Study Links E-Cigarette Bans to Increased Cigarette Sales

Apr.08.2022
Study Links E-Cigarette Bans to Increased Cigarette Sales
A new study suggests that state-level e-cigarette bans are associated with increased cigarette sales.

According to foreign media reports, a new study suggests that a national ban on e-cigarettes is linked to an increase in cigarette sales. The study, published in the scientific journal "Health Affairs," adds to mounting evidence that banning the sale of e-cigarettes may lead more people to revert back to smoking, which is less safe than using nicotine alternatives.

 

During a three-month study, it was found that an additional 3.4 million cigarette packs were sold through convenience stores across three states.

 

Researchers have used state-level cigarette sales data to discover that Massachusetts, which has implemented a complete ban on nicotine e-cigarettes, has seen a 7.5% increase in per capita cigarette sales compared to expectations. Rhode Island and Washington, which have enacted bans on non-tobacco flavored nicotine e-cigarettes, have an average estimated increase of 4.6% in per capita cigarette sales compared to expectations. Based on actual and estimated cigarette sales, the researchers suggest that an additional 3.4 million cigarette packs were sold in convenience stores across the three states during the three-month study period following the implementation of their respective bans.

 

The study was sponsored by Juul Labs, but has had little impact thus far, possibly due to the belief among many in the tobacco control field that research funded by the industry is biased. This debate may stem from decades of data suppression by big tobacco companies, which has recently resurfaced. For example, the Society for Research on Nicotine and Tobacco (SRNT) now explicitly prohibits industry-sponsored speakers from presenting at its conferences, a move that has led to resignations and condemnation of current tobacco control as "anti-scientific".

 

Researchers examined data from the fall of 2019, when legislators began paying attention to a series of mysterious lung diseases referred to as EVALI, which were quickly associated with e-cigarettes by politicians. Although by November 2019, the Centers for Disease Control and Prevention (CDC) had attributed most cases to contaminated illegal THC cartridges, state governments still stirred up panic and sought emergency bans, which in some cases became permanent.

 

In response to the EVALI outbreak, Massachusetts instituted an emergency ban on all nicotine e-cigarettes starting on September 24, 2019. Rhode Island and Washington followed suit, implementing four-month emergency bans on non-tobacco flavored nicotine e-cigarettes on October 4, 2019, and October 10, 2019, respectively. Massachusetts has since permanently banned the sale of flavored e-cigarette products, including menthol, while Rhode Island and Washington's emergency bans have expired, though a permanent flavor ban remains on the table.

 

Previous research has found similar results to those presented in health value papers.

 

The use of nicotine has not been linked to any diagnosis of EVALI in the field of medicine, but misinformation continues to spread. Under the guidance of sensationalist reporting by policymakers and the media, concerns over the rates of youth vaping have directly sparked fears over deadly vaping products. Misleading information is simple: youth are using e-cigarettes and, in some cases, dying from them. Over two years have passed since the outbreak, and the Centers for Disease Control and Prevention (CDC) in the US have yet to release any formal correction stating that nicotine e-cigarettes are not associated with lung injuries.

 

Previous research has yielded similar results to the findings of a health-focused paper. Co-authors from Boston University published an article in the Harm Reduction Journal indicating that misunderstandings surrounding EVALI (e-cigarette or vaping product use-associated lung injury) – which led to a ban in Massachusetts – appeared to have increased cigarette consumption across Boston. Moreover, Dr. Abigail Friedman from Yale University found in JAMA Pediatrics that after San Francisco banned flavored e-cigarettes and tobacco products, high schoolers in the city were more likely to smoke than their peers in other similar districts across the US.

 

(Source: Filter)

 

Restrictions on vaping products may have unintended consequences, including an increase in cigarette sales. While policymakers have focused on limiting access to e-cigarettes, they may inadvertently be pushing consumers back to traditional tobacco products. This is especially problematic given the well-documented health risks associated with smoking. It remains to be seen whether tighter regulations on vaping will have the intended impact of reducing nicotine addiction overall.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
PMI Launches Fourth IQOS Convenience-Store Discount of 2026 for Black Friday in Japan, Cutting ILUMA i ONE to About $19 After Ploom AURA Fell to About $9
Philip Morris Japan launched its fourth confirmed nationwide convenience-store discount campaign for IQOS ILUMA i devices in 2026 on October 26, cutting three models by as much as ¥2,000, or about $12.70. The campaign began one day after JT ended a promotion that reduced Ploom AURA to ¥1,480, or about $9.40. JT says Ploom's share of Japan's heated-products category rose from 10.9% in January 2024 to 18.3% in June 2026, a gain of 7.4 percentage points, while PMI says IQOS still held about 68% category share in the third quarter. At the same time, Japan's two-stage heated-tobacco tax adjustment has pushed stick prices higher, leaving device discounts as an increasingly important tool for lowering the upfront cost of customer acquisition.
Market
Oct.28
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11